Study shows variability in response to long-term tamsulosin therapy

In this video, Scott R. Bauer, MD, ScM, discusses findings from a randomized N-of-1 trial examining whether older men receiving long-term tamsulosin for lower urinary tract symptoms (LUTS) may benefit from deprescribing. Bauer is an associate professor of medicine, urology, epidemiology, and biostatistics at the University of California, San Francisco.

Bauer explains that the study was motivated by questions about whether lifelong alpha-blocker therapy provides the same degree of benefit to all men with LUTS attributed to benign prostatic hyperplasia (BPH). The double-blind, placebo-controlled trial enrolled men aged 55 to 80 years who had been taking tamsulosin for at least 12 months. Following a 1-week placebo run-in, participants alternated between 2-week blocks of their usual tamsulosin dose and matching placebo over 12 weeks, while completing daily assessments of their urinary symptoms and potential treatment-related adverse effects. Bauer notes that the findings are applicable specifically to men who can initially tolerate at least 1 week off tamsulosin.

Among 31 enrolled participants, 26 completed the full N-of-1 trial after 4 men were unable to tolerate the initial placebo run-in because of worsening symptoms and 1 participant withdrew for an unrelated surgery. Treatment response varied substantially, with individual differences in daily American Urological Association Symptom Index scores between tamsulosin and placebo ranging from -10.9 to 2.1. Of the participants who completed the protocol, 11 (36.7%) had minimal or no symptomatic benefit from tamsulosin, 11 (36.7%) had a moderate response, and 4 (13.3%) had a strong response. Bauer also highlights that commonly reported tamsulosin adverse effects were frequently reported during both tamsulosin and placebo periods, suggesting that many symptoms attributed to the medication may not have been caused by tamsulosin itself.

The findings suggest that treatment response to long-term tamsulosin therapy is heterogeneous and that approximately 1 in 3 older men who can tolerate an initial period off therapy may have minimal or no symptomatic benefit from continued treatment. Bauer emphasizes that N-of-1 deprescribing trials could provide a practical way to identify individual patients who may be appropriate candidates for discontinuing chronic alpha-blocker therapy while accounting for the substantial variability in treatment response.

REFERENCE